Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan.
Salk JJ, Loubet-Senear K, Maritschnegg E, Valentine CC, Williams LN, Higgins JE, Horvat R, Vanderstichele A, Nachmanson D, Baker KT, Emond MJ, Loter E, Tretiakova M, Soussi T, Loeb LA, Zeillinger R, Speiser P, Risques RA. Salk JJ, et al. Among authors: maritschnegg e. Cell Rep. 2019 Jul 2;28(1):132-144.e3. doi: 10.1016/j.celrep.2019.05.109. Cell Rep. 2019. PMID: 31269435 Free PMC article.
Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study.
Maritschnegg E, Wang Y, Pecha N, Horvat R, Van Nieuwenhuysen E, Vergote I, Heitz F, Sehouli J, Kinde I, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Speiser P, Zeillinger R. Maritschnegg E, et al. J Clin Oncol. 2015 Dec 20;33(36):4293-300. doi: 10.1200/JCO.2015.61.3083. Epub 2015 Nov 9. J Clin Oncol. 2015. PMID: 26552420 Free PMC article.
Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells.
Obermayr E, Maritschnegg E, Agreiter C, Pecha N, Speiser P, Helmy-Bader S, Danzinger S, Krainer M, Singer C, Zeillinger R. Obermayr E, et al. Among authors: maritschnegg e. Oncotarget. 2017 Nov 28;9(1):812-823. doi: 10.18632/oncotarget.22549. eCollection 2018 Jan 2. Oncotarget. 2017. PMID: 29416657 Free PMC article.
A comparison of four technologies for detecting p53 aggregates in ovarian cancer.
Heinzl N, Koziel K, Maritschnegg E, Berger A, Pechriggl E, Fiegl H, Zeimet AG, Marth C, Zeillinger R, Concin N. Heinzl N, et al. Among authors: maritschnegg e. Front Oncol. 2022 Sep 8;12:976725. doi: 10.3389/fonc.2022.976725. eCollection 2022. Front Oncol. 2022. PMID: 36158680 Free PMC article.
Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
Heinzl N, Maritschnegg E, Koziel K, Schilhart-Wallisch C, Heinze G, Yang WL, Bast RC, Sehouli J, Braicu EI, Vergote I, Van Gorp T, Mahner S, Paspalj V, Grimm C, Obermayr E, Schuster E, Holzer B, Rousseau F, Schymkowitz J, Concin N, Zeillinger R. Heinzl N, et al. Among authors: maritschnegg e. Oncogene. 2023 Aug;42(33):2473-2484. doi: 10.1038/s41388-023-02758-8. Epub 2023 Jul 4. Oncogene. 2023. PMID: 37402882